Core Insights - Nektar Therapeutics has sufficient financial resources to fund its operations into early 2027, with a strong positive investor reaction following its latest quarterly earnings report [1][4] - The company reported total revenue of just under $11.2 million for the second quarter, significantly lower than the nearly $23.5 million reported in the same period of 2024, primarily deriving from noncash royalty revenue [2][4] - Nektar's net loss for the second quarter was slightly over $39 million, equating to $2.78 per share, which was higher than analysts' projections of a net loss of only $0.20 per share [4][5] Financial Performance - Total revenue for the second quarter was just under $11.2 million, down from nearly $23.5 million in the same quarter of 2024 [2] - The company's cash and investments in marketable securities were reported at just under $176 million at the end of the quarter, supplemented by approximately $107.5 million expected from a recent secondary share issue [4] - The net loss for the second quarter was slightly over $39 million, or $2.78 per share [4] Market Reaction - Following the earnings report, Nektar's share price increased by 6%, outperforming the S&P 500 index, which gained only 0.8% [1] Future Prospects - Nektar highlighted several potential tailwinds, including the U.S. FDA granting Fast Track designation for its investigational drug rezpegaldesleukin, aimed at treating severe-to-very-severe alopecia areata [6]

Key Takeaways Nektar's Q2 loss of $2.95 per share and revenues beat estimates.Revenues fell after the 2024 sale of the Huntsville facility, ending product revenue streams.Phase IIb trials on rezpeg for atopic dermatitis and alopecia areata are moving forward.Nektar Therapeutics (NKTR) reported a loss of $2.95 per share for the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $3.13. In the year-ago quarter, the company had reported a loss of $3.76 per share.Excluding the impact ...

Nektar Therapeutics (NKTR) Q2 2025 Earnings Call August 07, 2025 05:00 PM ET Speaker0Hello, and thank you for standing by. Welcome to the Nectar Therapeutics Second Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded.I would now like to hand the conference over to Corinne Franklin from Therapeutics Inves ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Commission File Number: 0-24006 NEKTAR THERAPEUTICS ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

Exhibit 99.1 Nektar Therapeutics Reports Second Quarter 2025 Financial Results SAN FRANCISCO, August 7, 2025 -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025. "We are proceeding in our IND-enabling studies for our next T reg program, NKTR-0165, which targets the TNFR2 receptor to stimulate tissue-specific T regulatory cells," continued Robin. "Our goal is to advance NKTR-0165 into the clinic in 2026. Finally, we are making significant progress ...

Core Viewpoint - Nektar Therapeutics reported its financial results for Q2 2025, highlighting a significant decrease in revenue year-over-year, primarily due to the sale of its Huntsville manufacturing facility, while also showcasing promising clinical data for its lead product candidate, rezpegaldesleukin, in treating autoimmune disorders [1][4][3]. Financial Performance - Cash and investments in marketable securities as of June 30, 2025, were $175.9 million, down from $269.1 million on December 31, 2024. This figure does not include $107.5 million from a secondary offering completed on July 2, 2025, which is expected to support operations into Q1 2027 [2]. - Revenue for Q2 2025 was $11.2 million, a decrease from $23.5 million in Q2 2024. For the first half of 2025, revenue totaled $21.6 million compared to $45.1 million in the same period of 2024 [4]. - Total operating costs and expenses in Q2 2025 were $47.4 million, down from $73.3 million in Q2 2024. For the first half of 2025, total operating costs were $102.4 million compared to $130.3 million in the first half of 2024 [5]. - R&D expenses in Q2 2025 were $29.9 million, slightly up from $29.7 million in Q2 2024. For the first half of 2025, R&D expenses were $60.4 million compared to $57.1 million in the first half of 2024 [6]. - General and administrative expenses were $17.1 million in Q2 2025, down from $20.5 million in Q2 2024. For the first half of 2025, G&A expenses were $41.4 million compared to $40.7 million in the first half of 2024 [7]. - The net loss for Q2 2025 was $41.6 million, or $2.95 per share, compared to a net loss of $52.4 million, or $3.76 per share, in Q2 2024. The net loss for the first half of 2025 was $92.5 million, or $6.57 per share, compared to a net loss of $89.2 million, or $6.63 per share, in the first half of 2024 [10]. Clinical Developments - Nektar announced transformative data for rezpegaldesleukin from a Phase 2b study in patients with moderate to severe atopic dermatitis, showing rapid onset of EASI response and itch relief. The company anticipates reporting 52-week data in early 2026 [3]. - The company is advancing its next T regulatory cell program, NKTR-0165, targeting the TNFR2 receptor, with plans to enter clinical trials in 2026. Additionally, preclinical studies for a new bispecific antibody, NKTR-0166, are progressing [3]. - In July 2025, the FDA granted Fast Track designation for rezpegaldesleukin for treating severe-to-very severe alopecia areata in adults and pediatric patients [17]. Recent Business Highlights - Nektar successfully closed a public offering of its common stock in July 2025, raising $115 million in gross proceeds [17]. - The REZOLVE-AD study achieved statistical significance on primary and key secondary endpoints at week 16, indicating the potential of rezpegaldesleukin as a first and best-in-class immune-modulator [17].

SAN FRANCISCO, July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page ...

Core Insights - Investing in biotechnology stocks involves long periods of inactivity followed by sharp movements, particularly in small-cap biotech stocks which often lack profitability and revenue [1][2] Group 1: Urogen Pharma - UroGen Pharma is focused on treating urologic cancers with its proprietary RTGel technology, enhancing drug efficacy by prolonging retention in the urinary tract [4] - UroGen stock has increased approximately 43% in 2025 due to an application to expand the Jelymyto label for low-grade bladder cancer, potentially increasing its market [5] - Analyst forecasts suggest a price target of $32.86 for URGN stock, indicating a potential gain of over 115% from its closing price on July 18, although short interest is high at over 42% [6] Group 2: Nektar Therapeutics - Nektar Therapeutics has seen a 78% gain in 2025 but remains down over 93% in the last five years due to several clinical trial failures [8] - Positive Phase 2b clinical trial results for a candidate treating systemic lupus erythematosus and ulcerative colitis have generated bullish sentiment, along with a Fast Track designation from the FDA [9] - The consensus price target for NKTR stock is $88.33, representing a 254% increase from its closing price on July 18, but a pullback is anticipated due to recent price surges [10] Group 3: Verve Therapeutics - Verve Therapeutics is pioneering gene editing to treat cardiovascular disease, currently in the clinical stage with revenue primarily from partnerships [12] - The company received approval for a Phase 1b U.S. clinical trial for its lead candidate, VERVE-102, targeting the PCSK9 gene associated with high cholesterol [13] - Analysts have set a price target of $14.57 for VERV stock, indicating a 33% upside, although this is lower compared to the other stocks mentioned [13]

Core Viewpoint - Nektar Therapeutics experienced a decline in stock price following the completion of a secondary stock issue, resulting in a 3% loss, while the S&P 500 index rose by 0.8% [1] Group 1: Capital Raise Details - Nektar completed a secondary share flotation, selling slightly more than 4.89 million shares of common stock, including 638,298 shares sold to underwriters [2] - The gross proceeds from the share issue were approximately $115 million, priced at $23.50 per share, intended for general corporate purposes, including drug development and research activities [4] Group 2: Impact on Shareholders - The secondary share flotation is dilutive to existing shareholders, increasing the total share count from slightly more than 12.4 million to nearly 17.4 million shares, which negatively impacts shareholder value [5] - Investors are concerned about potential future equity offerings, which could lead to further dilution of shares [7] Group 3: Company Pipeline and Potential - Nektar has several pipeline projects in development, with its leading candidate, rezpegaldesleukin, showing promising results for treating moderate-to-severe atopic dermatitis [6]

Group 1 - Nektar Therapeutics closed an underwritten public offering of $115 million, selling 4,893,618 shares at a price of $23.50 per share [1][2] - The offering included 638,298 shares sold due to the underwriters' full exercise of their option to purchase additional shares [1] - The gross proceeds from the offering are approximately $115 million before deducting underwriting discounts and commissions [1] Group 2 - Nektar plans to use the net proceeds for general corporate purposes, including research and development, clinical development, and manufacturing costs [2] - Jefferies and Piper Sandler acted as joint bookrunning managers, with BTIG, LLC and H.C. Wainwright & Co. also involved in the offering [2] Group 3 - The securities were offered under a shelf registration statement filed with the SEC on March 28, 2025, and declared effective on April 1, 2025 [3] - A final prospectus supplement related to the offering is available on the SEC's website [4] Group 4 - Nektar Therapeutics is focused on developing treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate being rezpegaldesleukin (REZPEG, or NKTR-358) [6] - The company is evaluating several drug candidates, including NKTR-255, an investigational IL-15 receptor agonist designed to enhance the immune system's ability to fight cancer [6]